Schildklier en psyche

Plaats hier (verwijzingen naar) literatuur, onderzoeken en andere bronnen van kennis over hypothyroïdie.
Discussies over artikelen s.v.p. in het HypoCafé.

Schildklier en psyche

Berichtdoor HypoForum » zondag 30 januari 2005 - 0:33

Deze auteur had een praatje op het europees schildkliercongress over T4/T3 replacement therapie naar aanleiding van onderstaand abstract.
Nog even afwachten of het ook tot een artikel leidt. Kortom in de gaten houden dus.



Dit is dus een voorstudie.
Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study.

Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM.

Weston General Hospital, Weston-Super-Mare, Bristol, UK.

OBJECTIVE: Over 1% of the UK population is receiving thyroid hormone replacement with l-thyroxine (T4). However, many patients complain of persistent lethargy and related symptoms on T4 even with normal TSH levels. To date there has been no large study to determine whether this is related to thyroxine replacement or coincidental psychological morbidity. We have therefore attempted to address this issue using a large, community-based study. DESIGN AND PATIENTS: Computerized prescribing records of five general practices were used to identify 961 patients who had been on thyroxine for a minimum of 4 months from a population of 63 000 (1.5%), along with age- and sex-matched controls. All 1922 individuals were sent a two-page questionnaire, made up of the short form of the General Health Questionnaire (GHQ-12), designed to detect minor psychiatric disorders in the community, and a 12-question 'thyroid symptom questionnaire' (TSQ) in the same format. A covering letter explained that we were interested in 'how patients felt on medication' and made no direct reference to thyroxine. MEASUREMENTS: Scores from the GHQ and TSQ were marked for each individual using the GHQ and Likert scoring methods. Patients' latest TSH measurements were obtained from laboratory records. Comparisons were then made on scores for the total GHQ-12, TSQ and individual questions between patients (P) and control (C) groups. Separate analyses were made comparing the patients with a normal TSH (nP) and the control group. RESULTS: Five hundred and ninety-seven (62%) of the patients (P) and 551 (57%) of the controls (C) responded and fully completed at least one of the two questionnaire. Three hundred and ninety-seven responding patients (nP) had a TSH estimation performed in the previous 12 months with the last result being in the local laboratory normal range for TSH (0.1-5.5 or 0.2-6.0 mU/l, according to the assay method used). The responding P, nP and C populations were well matched for age (59.96, 59.73, 59.35 years) and sex (85%, 83%, 87% female). The number of individuals scoring 3 or more on the GHQ-12 (indicating 'caseness') was 21% higher in P than C [185/572 (32.3%) vs. 137/535 (25.6%), P = 0.014] and 26% higher in nP than C [131/381 (34.4%) vs. 137/535 (25.6%), P < 0.005]. Stronger differences were seen with the TSQ scores [C = 187/535 (35.0%), P = 273/583 (46.8%), P < 0.001, P vs. C; and nP = 189/381 (48.6%), P < 0.001, nP vs. C]. Differences existed in chronic drug use and chronic disease prevalence between the control and patient groups, but the differences in GHQ and TSQ scores between the groups remained significant even after correction for these factors as well as age and sex in multiple regression analysis. CONCLUSIONS: This community-based study is the first evidence to indicate that patients on thyroxine replacement even with a normal TSH display significant impairment in psychological well-being compared to controls of similar age and sex. In view of the large numbers of people on thyroxine replacement, we believe that these differences, although not large, could contribute to significant psychological morbidity in a substantial number of individuals.

PMID: 12390330 [PubMed - indexed for MEDLINE]
<b>Onder de gebruikersnaam "Forumbeheer" worden beheer-activiteiten uitgevoerd door: Gabriëla, Esterelle, Lisatje en Zazoo.</b> <br>forum@hypomaarniethappy.nl<p><img src="http://www.hypomaarniethappy.nl/worm.gif">
Avatar gebruiker
HypoForum
Beheerster
 
Berichten: 166
Geregistreerd: donderdag 27 januari 2005 - 18:31

Berichtdoor HypoForum » zondag 30 januari 2005 - 0:34

WESTON AREA T4/T3 (THYROID HORMONE REPLACEMENT) STUDY: PSYCHOLOGICAL EFFECTS OF COMBINED REPLACEMENT THERAPY
(1)Saravanan P, (1)Simmons DJ, (2)Greenwood R, (3)Peters TJ, (1)Dayan CM. (1)University Research Centre for Neuroendocrinology, University of Bristol, Bristol, United Kingdom, (2)RDSU, Bristol Royal Infirmary, Bristol, United Kingdom, (3)Dept of Primary Care, University of Bristol, Bristol, United Kingdom
Background & Aims: We have previously demonstrated a 6% absolute increase in ¡°psychiatric caseness¡± (by General Health Questionnaire-12) in patients on thyroxine with normal TSH compared to controls. In view of a recent report of improved psychological wellbeing in patients receiving combined T4/T3, we studied the possible beneficial effects of such therapy in a large community based randomised controlled study.Methods: 697 patients on ¡Ý100mcg of thyroxine were randomised to 10mcg of T3 in place of 50mcg of T4 (Study,S) or no change in their T4 dose (Control,C). The primary outcome measurement was the GHQ-12 score, both by the Likert (continuous score ¨C 0,1,2,3) and the traditional, bimodal GHQ scoring (0,0,1,1) methods, at 3 months adjusting for baseline GHQ-12 scores. A threshold of ¡Ý3 by the GHQ scoring method was used to indicate ¡°caseness¡± (significant psychological morbidity), as in our previous study. Secondary psychological outcomes included 23 visual analogue scales.Results: Baseline characteristics were similar between the 2 groups [S:C = Age (57.1:57.6yrs), % female (83.4:84.2), % primary hypothyroidism (71.3:71.9), dose of T4 (127.3:123.0mcg), years on T4 (11.8:10.8yrs) & baseline GHQ scores (13.41:13.44)]. Using the Likert scoring, there was a tendency towards an improvement in GHQ-12 scores on combined T3/T4 but this did not reach statistical significance (S minus C = -0.43; 95% CI at -1.12, +0.26; p=0.22). Additionally, no difference was observed in 23 different visual analogue scales. However, using the GHQ scoring method to indicate "caseness" an odds ratio of reducing ¡°caseness¡± of 1.56 was observed (95% CI at 1.04 to 2.34; p=0.03) in favour of combined therapy. Conclusions: In the setting of a large community based randomised, double-blind controlled trial, combined replacement with 10mcg of T3 in place of 50mcg of T4 may improve the psychological wellbeing of patients. Adjustments in regimen may be required for optimal benefit.
<b>Onder de gebruikersnaam "Forumbeheer" worden beheer-activiteiten uitgevoerd door: Gabriëla, Esterelle, Lisatje en Zazoo.</b> <br>forum@hypomaarniethappy.nl<p><img src="http://www.hypomaarniethappy.nl/worm.gif">
Avatar gebruiker
HypoForum
Beheerster
 
Berichten: 166
Geregistreerd: donderdag 27 januari 2005 - 18:31


Keer terug naar Waardevolle informatie met bronvermelding

Wie is er online

Gebruikers op dit forum: Geen geregistreerde gebruikers. en 1 gast

cron